Pharmacokinetics and pharmacodynamics of pentopril, a new angiotensin-converting-enzyme inhibitor in humans

• Published in: Journal of clinical pharmacology Vol. 26; no. 3; p. 156
• Main Authors: Rakhit, A, Hurley, M E, Tipnis, V, Coleman, J, Rommel, A, Brunner, H R
• Format: Journal Article
• Language: English
• Published: England 01.03.1986
• Subjects: Administration, Oral; Adult; Angiotensin I - pharmacology; Angiotensin-Converting Enzyme Inhibitors; Biotransformation; Blood Pressure - drug effects; Drug Administration Schedule; Humans; Indoles - administration & dosage; Indoles - metabolism; Indoles - pharmacology; Intestinal Absorption; Kinetics; Male; Mathematics; Models, Biological; Peptidyl-Dipeptidase A - blood
• ISSN: 0091-2700
• DOI: 10.1002/j.1552-4604.1986.tb02927.x

In a single, ascending-dose tolerance study, nine healthy volunteers were given oral pentopril 50 to 750 mg (CGS 13945) in groups of three each. Disposition characteristics of pentopril and its active metabolite (CGS 13934) were determined using plasma concentration and urinary excretion data. The drug was absorbed rapidly following zero-order kinetics. The drug has an apparent volume of distribution of 0.83 L/kg and an oral clearance of about 0.79 L/hr/kg. Urinary excretions, calculated after 125- and 250-mg doses, showed a dose proportional urinary recovery of 21% (+/- 5%) for pentopril and 40% (+/- 5%) for CGS 13934. In the multiple-dose study of 125 mg orally q12h in six healthy subjects, the plasma concentrations for both drug and metabolite showed no appreciable accumulation of either compound, which was expected from their short pharmacokinetic half-lives (pentopril, less than 1 hr; CGS 13934, approximately 2 hr). In a separate pharmacodynamic study, drug and metabolite concentrations were evaluated against angiotensin-I (AI)-induced changes in blood pressure and plasma angiotensin-converting-enzyme (ACE) activity in healthy volunteers after single oral doses (range, 10-500 mg). The pharmacodynamic half-life for plasma ACE inhibition increased with the dose (10 mg, 1.5 hr; 500 mg, 9.8 hr). There was a close relationship between the plasma level of the metabolite and the inhibition of plasma ACE activity and AI-induced pressor response. A hyperbolic function adequately described the dependence of plasma ACE activity on plasma metabolite concentration with a concentration at half-maximal inhibition of 53 ng/mL.